Neeraj Agarwal

13.2k total citations · 1 hit paper
207 papers, 4.8k citations indexed

About

Neeraj Agarwal is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Neeraj Agarwal has authored 207 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Pulmonary and Respiratory Medicine, 63 papers in Cancer Research and 60 papers in Oncology. Recurrent topics in Neeraj Agarwal's work include Renal cell carcinoma treatment (79 papers), Prostate Cancer Treatment and Research (58 papers) and Cancer Genomics and Diagnostics (49 papers). Neeraj Agarwal is often cited by papers focused on Renal cell carcinoma treatment (79 papers), Prostate Cancer Treatment and Research (58 papers) and Cancer Genomics and Diagnostics (49 papers). Neeraj Agarwal collaborates with scholars based in United States, Canada and Denmark. Neeraj Agarwal's co-authors include Toni K. Choueiri, Ulka N. Vaishampayan, Sumanta K. Pal, Frede Donskov, Lori Wood, Brian I. Rini, Daniel Y.C. Heng, Sun Young Rha, Georg A. Bjarnason and Christian Kollmannsberger and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Neeraj Agarwal

194 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

2013 730 citations Daniel Y.C. Heng, Lauren C. Harshman et al. profile →

Peers

Countries citing papers authored by Neeraj Agarwal

Since Specialization

Citations

This map shows the geographic impact of Neeraj Agarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neeraj Agarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neeraj Agarwal more than expected).

Fields of papers citing papers by Neeraj Agarwal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neeraj Agarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neeraj Agarwal. The network helps show where Neeraj Agarwal may publish in the future.

Co-authorship network of co-authors of Neeraj Agarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Neeraj Agarwal. A scholar is included among the top collaborators of Neeraj Agarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neeraj Agarwal. Neeraj Agarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY 2025 ·Urologic Oncology Seminars and Original Investigations ·Neeraj Agarwal, Michael T. Schweizer, Elena Castro, Arun Azad, Daniel J. George, Jayeta Chakrabarti, Sujata Narayanan, Yiyun Tang, Karim Fizazi	1
2	Photocytotoxic and cellular metabolism studies of curcuminoid-BF2 nanoaggregates in human carcinoma cells 2024 ·Journal of Photochemistry and Photobiology A Chemistry ·(unknown), (unknown), Sandeep B. Shelar, (unknown), Angelika Rück, P. A. Hassan, K.C. Barick, Neeraj Agarwal	0
3	Comparative study of tamsulosin, tadalafil, and combination of tamsulosin with tadalafil in the treatment of patients with lower urinary tract symptoms 2024 ·Urological Science ·(unknown), Neeraj Agarwal, Dilip Kumar Pal	1
4	The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage 2022 ·Cancer Discovery ·Gilberto Morgan, Neeraj Agarwal, Toni K. Choueiri, Don S. Dizon, Erika Hamilton, Merry Jennifer Markham, Mark A. Lewis, Tatiana M. Prowell, Hope S. Rugo, Vivek Subbiah, Howard West	11
5	First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis 2019 ·European Urology Oncology ·Andrew W. Hahn, Zachary Klaassen, Neeraj Agarwal, Benjamin Haaland, (unknown), Xiang Y. Ye, Xuechen Wang, Sumanta K. Pal, Christopher J.D. Wallis	68
6	Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer 2019 ·Cancer ·Guru Sonpavde, Neeraj Agarwal, Gregory R. Pond, Rebecca J. Nagy, Roberto Nussenzveig, Andrew W. Hahn, Oliver Sartor, Theodore Stewart Gourdin, Lakshminarayanan Nandagopal, Elisa M. Ledet, Gurudatta Naik, Andrew J. Armstrong, Jue Wang, Mehmet Asım Bilen, Shilpa Gupta, Petros Grivas, Sumanta K. Pal, Richard B. Lanman, AmirAli Talasaz, Michelle M. Lilly	41
7	Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer 2019 ·Urologic Oncology Seminars and Original Investigations ·Andrew W. Hahn, David D. Stenehjem, Anitha Alex, David Gill, Heather H. Cheng, Elizabeth R. Kessler, (unknown), Przemyslaw Twardowski, Ulka N. Vaishampayan, Neeraj Agarwal	2
8	Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time 2019 ·Cancer Treatment and Research Communications ·Andrew W. Hahn, David D. Stenehjem, Roberto Nussenzveig, (unknown), Erin Bailey, (unknown), Benjamin L. Maughan, Neeraj Agarwal	13
9	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database 2019 ·European Urology Oncology ·Marco Moschini, Évanguelos Xylinas, Stefania Zamboni, Agostino Mattei, Günter Niegisch, Evan Y. Yu, Aristotelis Bamias, Neeraj Agarwal, Srikala S. Sridhar, Cora N. Sternberg, Ulka N. Vaishampayan, Jonathan E. Rosenberg, Joaquim Bellmunt, Matthew D. Galsky, Francesco Montorsi, Andrea Necchi	35
10	Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC) 2018 ·Molecular Cancer Therapeutics ·Andrew W. Hahn, David Gill, (unknown), Roberto Nussenzveig, (unknown), James M. Farnham, Robert A. Stephenson, Lisa Cannon‐Albright, Benjamin L. Maughan, Neeraj Agarwal	9
11	A Study on Surgical Management of Distal Tibial Fractures by Using Minimally Invasive Technique of Percutaneous Plate Osteosynthesis with Locking Compression Plate 2018 ·International Journal of Health Sciences and Research ·Neeraj Agarwal, (unknown)	1
12	Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma 2017 ·Clinical Cancer Research ·Vivek Narayan, Stephen J. O’Keefe, Naomi B. Haas, Le Wang, Igor Puzanov, Mary Putt, Annamaria Catino, James C. Fang, Neeraj Agarwal, David M. Hyman, Amanda M. Smith, Brian S. Finkelman, Hari K. Narayan, Steven M. Ewer, Chantal ElAmm, Daniel J. Lenihan, Bonnie Ky	58
13	Benign diaphragmatic neurilemmoma mimicking a left adrenal cyst 2017 ·SHILAP Revista de lepidopterología ·(unknown), Vinay Tomar, (unknown), Neeraj Agarwal	3
14	Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer 2017 ·Clinical Genitourinary Cancer ·(unknown), David Gill, Andrew W. Hahn, Eric D. Johnson, (unknown), Kenneth M. Boucher, Roberto Nussenzveig, Benjamin L. Maughan, Neeraj Agarwal	7
15	Comparison of sonoelastography with sonourethrography and retrograde urethrography in the evaluation of male anterior urethral strictures 2016 ·SHILAP Revista de lepidopterología ·(unknown), Vinay Tomar, (unknown), (unknown), Shivam Priyadarshi, Neeraj Agarwal, (unknown)	11
16	A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin 2015 ·Cancer Chemotherapy and Pharmacology ·Neeraj Agarwal, Jordan P. McPherson, (unknown), Sumati Gupta, Theresa L. Werner, (unknown), Gajanan Bhat, Erin Bailey, Sunil Sharma	10
17	A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer 2013 ·Frontiers in Genetics ·(unknown), Neeraj Agarwal, Robert A. Stephenson, Lisa Cannon‐Albright	10
18	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients 2013 ·Targeted Oncology ·(unknown), Brian I. Rini, Lauren C. Harshman, Georg A. Bjarnason, Lori Wood, Ulka N. Vaishampayan, Mary J. MacKenzie, Jennifer J. Knox, Neeraj Agarwal, (unknown), Christian Kollmannsberger, Min-Han Tan, Sun Young Rha, Frede Donskov, Scott North, Toni K. Choueiri, Daniel Y.C. Heng	39
19	IMRT With Simultaneous Integrated Boost and Concurrent Chemotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck 2010 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Dennis C. Shrieve, Brandon G. Bentz, Jason P. Hunt, (unknown), Neeraj Agarwal, Ying J. Hitchcock	34
20	Anemia of Chronic Disease (Anemia of Inflammation) 2009 ·Acta Haematologica ·Neeraj Agarwal, Josef T. Prchal	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact